Overview

Hydroxychloroquine to Prevent SARS-CoV-2 Infection/COVID-19

Status:
Completed
Trial end date:
2020-11-23
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether hydroxychloroquine is an effective prophylactic regimen to prevent SARS-CoV-2 infection among healthcare workers. Participants will be randomized into two parallel groups. The first arm will evaluate the use of hydroxychloroquine every-other-day plus standard measures of protection for the prevention of SARS-CoV-2. The second arm will evaluate the use of standard measures of protection for the prevention of SARS-CoV-2. The target enrollment is 320 participants. Each study participant will be monitored for SARS-CoV-2 seroconversion in weekly visits or for the development of COVID-19 symptoms for 8 weeks.
Phase:
Phase 3
Details
Lead Sponsor:
Universidad Peruana Cayetano Heredia
Treatments:
Hydroxychloroquine